These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27048417)

  • 1. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.
    Iwamoto T; Kumamaru H; Miyata H; Tomotaki A; Niikura N; Kawai M; Anan K; Hayashi N; Masuda S; Tsugawa K; Aogi K; Ishida T; Masuoka H; Iijima K; Matsuoka J; Doihara H; Kinoshita T; Nakamura S; Tokuda Y
    Breast Cancer Res Treat; 2016 Apr; 156(3):485-494. PubMed ID: 27048417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
    Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
    Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.
    Barnes NL; Dimopoulos N; Williams KE; Howe M; Bundred NJ
    Eur J Surg Oncol; 2014 Mar; 40(3):249-54. PubMed ID: 24433818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nationwide breast cancer screening fully accomplished; results from the implementation phase 1990-1997. National Evaluation Team for Breast Cancer Screening].
    Ned Tijdschr Geneeskd; 2000 Jun; 144(23):1124-9. PubMed ID: 10876708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
    Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort.
    Saxby K; Nickson C; Mann GB; Velentzis L; Bromley HL; Procopio P; Canfell K; Petrie D
    Aust N Z J Public Health; 2020 Jun; 44(3):219-226. PubMed ID: 32311194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
    van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
    Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011.
    Kurebayashi J; Miyoshi Y; Ishikawa T; Saji S; Sugie T; Suzuki T; Takahashi S; Nozaki M; Yamashita H; Tokuda Y; Nakamura S
    Breast Cancer; 2015 May; 22(3):235-44. PubMed ID: 25758809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.
    Musolino A; Michiara M; Conti GM; Boggiani D; Zatelli M; Palleschi D; Bella MA; Sgargi P; Di Blasio B; Ardizzoni A
    J Clin Oncol; 2012 Jul; 30(19):2362-8. PubMed ID: 22585698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; de Vries J; Wesseling J; de Bock GH
    Ann Surg Oncol; 2007 Jul; 14(7):2097-104. PubMed ID: 17453296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proportion of breast cancer in women aged 50 to 69 years from Girona, Spain, according to detection method].
    Puig-Vives M; Osca-Gelis G; Camprubí-Font C; Vilardell ML; Izquierdo A; Marcos-Gragera R
    Med Clin (Barc); 2014 Oct; 143(7):300-2. PubMed ID: 24378145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
    Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
    Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
    Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
    Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First epidemiological analysis of breast cancer incidence and tumor characteristics after implementation of population-based digital mammography screening.
    Weigel S; Batzler WU; Decker T; Hense HW; Heindel W
    Rofo; 2009 Dec; 181(12):1144-50. PubMed ID: 19859859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study.
    Ponti A; Ronco G; Lynge E; Tomatis M; Anttila A; Ascunce N; Broeders M; Bulliard JL; Castellano I; Fitzpatrick P; Frigerio A; Hofvind S; Májek O; Segnan N; Taplin S;
    Breast Cancer Res Treat; 2019 Oct; 177(3):761-765. PubMed ID: 31250357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential impact of USPSTF recommendations on early diagnosis of breast cancer.
    Aragon R; Morgan J; Wong JH; Lum S
    Ann Surg Oncol; 2011 Oct; 18(11):3137-42. PubMed ID: 21947591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.